271 related articles for article (PubMed ID: 11884495)
1. A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
Siegel JA; Kroll S; Regan D; Kaminski MS; Wahl RL
J Nucl Med; 2002 Mar; 43(3):354-63. PubMed ID: 11884495
[TBL] [Abstract][Full Text] [Related]
2. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy.
Gates VL; Carey JE; Siegel JA; Kaminski MS; Wahl RL
J Nucl Med; 1998 Jul; 39(7):1230-6. PubMed ID: 9669400
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members.
Rutar FJ; Augustine SC; Kaminski MS; Wahl RL; Siegel JA; Colcher D
Clin Lymphoma; 2001 Dec; 2(3):164-72. PubMed ID: 11779293
[TBL] [Abstract][Full Text] [Related]
4. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy.
Siegel JA
J Nucl Med; 1998 Aug; 39(8 Suppl):28S-33S. PubMed ID: 9708568
[TBL] [Abstract][Full Text] [Related]
5. Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members.
Rutar FJ; Augustine SC; Colcher D; Siegel JA; Jacobson DA; Tempero MA; Dukat VJ; Hohenstein MA; Gobar LS; Vose JM
J Nucl Med; 2001 Jun; 42(6):907-15. PubMed ID: 11390555
[TBL] [Abstract][Full Text] [Related]
6. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab.
Wahl RL
Semin Oncol; 2003 Apr; 30(2 Suppl 4):31-8. PubMed ID: 12728405
[TBL] [Abstract][Full Text] [Related]
7. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
8. Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab.
Hohenstein MA; Augustine SC; Rutar F; Vose JM
Semin Oncol; 2003 Apr; 30(2 Suppl 4):39-49. PubMed ID: 12728406
[TBL] [Abstract][Full Text] [Related]
9. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
[TBL] [Abstract][Full Text] [Related]
10. The need for better methods to determine release criteria for patients administered radioactive material.
Sparks RB; Siegel JA; Wahl RL
Health Phys; 1998 Oct; 75(4):385-8. PubMed ID: 9753361
[TBL] [Abstract][Full Text] [Related]
11. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
Koral KF; Dewaraja Y; Li J; Lin Q; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2003 Mar; 44(3):457-64. PubMed ID: 12621015
[TBL] [Abstract][Full Text] [Related]
12. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
[TBL] [Abstract][Full Text] [Related]
13. Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma.
Rajendran J; Gopal A; Durack L; Fisher D; Press O; Eary J
Cancer Biother Radiopharm; 2004 Dec; 19(6):738-45. PubMed ID: 15665621
[TBL] [Abstract][Full Text] [Related]
14. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
[TBL] [Abstract][Full Text] [Related]
15. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
Vose JM; Wahl RL; Saleh M; Rohatiner AZ; Knox SJ; Radford JA; Zelenetz AD; Tidmarsh GF; Stagg RJ; Kaminski MS
J Clin Oncol; 2000 Mar; 18(6):1316-23. PubMed ID: 10715303
[TBL] [Abstract][Full Text] [Related]
17. Outpatient radioimmunotherapy with Bexxar. Closed, clean air reservoir minimizes personnel radiation exposure.
Harwood SJ; Gibbons LK; Goldner PJ; Webster WB; Carroll RG
Cancer; 2002 Feb; 94(4 Suppl):1358-62. PubMed ID: 11877766
[TBL] [Abstract][Full Text] [Related]
18. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.
Wahl RL; Kroll S; Zasadny KR
J Nucl Med; 1998 Aug; 39(8 Suppl):14S-20S. PubMed ID: 9708566
[TBL] [Abstract][Full Text] [Related]
19. The radioisotope contributes significantly to the activity of radioimmunotherapy.
Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
[TBL] [Abstract][Full Text] [Related]
20. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
